title: International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients.
abstract: BACKGROUND
  Most cystic fibrosis (CF) patients have exocrine pancreatic insufficiency (EPI) and need supplementation with pancreatic enzyme replacement therapy (PERT). Liprotamase, a novel non-porcine PERT containing highly purified biotechnology-derived lipase, protease, and amylase, has successfully undergone initial efficacy and safety testing.
  
  
  METHODS
  In this international phase III parallel-group, randomized-withdrawal, double-blind placebo-controlled trial, CF patients with EPI 7 years and older, including nutritionally and functionally compromised individuals, underwent baseline testing for coefficients of fat and nitrogen absorption (CFA and CNA) and stool weight and frequency while off PERT. After an open-label treatment period with liprotamase, subjects were randomized 1:1 to one liprotamase or placebo capsule taken with 3 meals and 2 snacks per day. The dose was fixed and increases were not allowed. The same measurements were obtained again after treatment with double-blind study drug or placebo.
  
  
  RESULTS
  138 subjects were randomized. The adjusted least squares mean (LSM) difference between the treatment and placebo groups for change in CFA was 15.1% (p=0.001) for the subgroup with baseline CFA <40%, 8.6% (p=0.006) for subjects with baseline CFA ≥40%, and 10.6% (p<0.001) for the overall intent-to-treat population. Similar results were seen for change in CNA. Stool weight was significantly decreased although not stool frequency. Liprotamase was well tolerated with no safety concerns identified.
  
  
  CONCLUSIONS
  In a CF patient population reflective of that encountered in clinical practice, this trial demonstrated that liprotamase at a fixed dose of one capsule per meal or snack (5 capsules per day) was well tolerated and significantly increased fat absorption as measured by improvement in CFA, significantly increased protein absorption as measured by improvement in CNA, and significantly decreased stool weight.
authors.affiliation: Division of Pediatric Pulmonology, State University of New York at Buffalo, Women and Children's Hospital of Buffalo, Buffalo, NY 14222, USA. dborowitz@upa.chob.edu
authors.forename: Drucy
authors.initials: D
authors.lastname: Borowitz
authors.forename: Christopher
authors.initials: C
authors.lastname: Stevens
authors.forename: Lee R
authors.initials: LR
authors.lastname: Brettman
authors.forename: Marilyn
authors.initials: M
authors.lastname: Campion
authors.forename: Barbara
authors.initials: B
authors.lastname: Chatfield
authors.forename: Marco
authors.initials: M
authors.lastname: Cipolli
mesh_terms: D000293:Adolescent; D000328:Adult; D000681:Amylases / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004311:Double-Blind Method; D056947:Enzyme Replacement Therapy; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007391:International Cooperation; D008049:Lipase / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010447:Peptide Hydrolases / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D008049:Lipase; D000681:Amylases; D010447:Peptide Hydrolases